Loading market information…
SHH · 688488.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Jiangsu Aidea Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Jiangsu Aidea Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jiangsu Aidea Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jiangsu Aidea Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and commercialization of diverse pharmaceutical products. Its extensive offerings encompass a range of medications including folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules. The company also provides pharmaceutical raw materials. Established in 2009, Jiangsu Aidea Pharmaceutical is headquartered in Yangzhou, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 |
|---|
| Oct 30, 2024 |
| -CN¥0.03 |
| CN¥117.81M+4.26% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
